


## Emosis – Take Away Notes from ISTH

The ISTH Congress in Berlin (July 8th – 13th) has been a formidable scene for worldwide key opinion leaders and young promising researchers from the Hemostasis & Thrombosis world to lecture on the latest developments in research and innovation. Thrombosis and Hemostasis have been studied and presented in correlation with various topics, from Oncology to Pediatrics, through Women Health; overall this congress enriched Emosis team's educational background.

Emosis also had the occasion to present its latest developments. Dr. Frederic Allemand, Emosis' CEO, took part to the Platelet Immunology sub-committee to introduce an audience of experts with the Flow Cytometry Assay (FCA) method conceived and developed by Emosis to routinely confirm Heparin-Induced Thrombocytopenia (HIT). He briefly explained the test principles and presented results of patient data analysis.



Emosis' presentations also included a much appreciated lecture by Dr. Brigitte Tardy during an Oral Communication on HIT, presenting the advantages of the benchtop FCA involved in HIT Confirm™ vs. the Serotonin Release Assay (SRA) method. Dr Tardy is a practitioner and a researcher from St-Etienne, France, specializing in Hemostasis and Thrombosis, and she lectured at ISTH to present the results of a study she led to assess the specificity of FCA vs. SRA when it comes to HIT diagnostic. The study included 290 patients, and showed that the FCA performed as well as the SRA when compared to clinical expert opinion.

Moreover, ISTH has been a great opportunity for all the Emosis team members to meet with interesting and interested contacts based worldwide, from North America to Asia and Australia, through Europe and Middle-East. Aurore Andre (CEO of Emosis Ltd based in Israel) met for instance with leading players of the Israeli haemostasis scene, initiating and reinforcing contacts for further R&D and business partnerships. Nicolas Rufin (Head of Sales and Marketing) introduced the visitors at our booth with HIT Confirm™, announcing its upcoming launch. HIT Confirm™ is a strong innovation in HIT diagnostics, by allowing routine, fast (90 minutes) on-

demand and user-friendly tests through benchtop flow cytometry. This assay provides a specificity comparable to the SRA's, while being more sensitive. HIT Confirm™ received a warm welcome, both from the scientific community and from potential future users.



We also welcomed on our stand many potential business partners, who showed immediate and strong interest for HIT Confirm™ and the paradigm shift it represents in the diagnostics of HIT, as well as for our forthcoming developments. Our new approach and expertise in cell-based haemostasis has been considered with enthusiasm, as our visitors saw the way it will help to enlighten their future medical decisions for a better patient care.

*« ISTH2017 was a tremendous success for Emosis, with many clinical labs over the world expressing interest for the Company's positioning on cell-based hemostasis assays, and for our first assay to come, HIT Confirm. This congress was truly a cornerstone! »* said Frederic Allemand, CEO of Emosis.

Berlin has been great, see you in Dublin next year!

---